Pegylated interferon-alfa–2a plus adefovir combination therapy is superior to pegylated interferon-alfa–2a alone or adefovir monotherapy in reducing HBsAg levels in HDV-coinfected…
H Wedemeyer, C Yurdaydin, K Zachou, A Erhardt, Y Cakaloglu, H Degertekin, S Gurel, S Zeuzem, G Dalekos, T Bock, HP Dienes, MP Manns · Zeitschrift für Gastroenterologie · 2007 · Heft 01
Bibliografische Angaben
Zusammenfassung
Introduction: Serum HBsAg levels are considered as a surrogate marker for intrahepatic HBV-cccDNA levels and have been shown to be reduced by adefovir therapy in HBV-monoinfected patients. The hepatitis D virus uses the HBsAg for virion formation. Thus, the best treatment option for HDV infection would be clearance of HBsAg. Methods: We investigated HBsAg levels in 90 patients with HBV-HDV coinfection being treated for 48 weeks with 180µg PEG-interferon-alfa–2a qw plus 10mg adefovir dipivoxil qd (group A, n=31), 180µg PEG-interferon-alfa–2a qw plus placebo (group B, n=29,) or 10mg adefovir dipivoxil qd alone (gr…
